Skip to main content
SpringerPlus

Table 2 Response rate (n = 31)

From: Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine

Response

n

%

Complete response

0

0

Partial response

3

9.7

Stable disease

6

19.4

Long stable disease

3

9.7

Progressive disease

19

61.3

Objective response rate

3

9.7

Clinical benefit rate

6

19.4

Back to article page